Motor fluctuations in levodopa treatment: Clinical pharmacology

European Neurology

Volumn 36, Issue , 1996, Pages 38-42

  Stocchi, F ^a   Bonamartini, A ^a   Vacca, L ^a   Ruggieri, S ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

L Dopa; Motor fluctuations; On off Dyskinesias; Parkinson s disease

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TRANSPORT; DYSKINESIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOTOR PERFORMANCE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; TIME;

ANTIPARKINSON AGENTS; DOPAMINE AGENTS; HUMANS; LEVODOPA; MOVEMENT DISORDERS; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; TREATMENT OUTCOME;

EID: 0030029826     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000118882     Document Type: Article

References (38)

1. Marttila RJ, Rinne UK, Sirtola T, Sonninen V: Mortality of patients with Parkinson’s disease treated with levodopa. J Neurol 1977;216:147-153.
2. Scigliano G, Musicco M, Soliveri P, Piccolo I, Girotti P, Caraceni T: Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 1990;40:265-269.
3. Sweet RD, McDowell FH: Five years’ treatment of Parkinson’s disease with levodopa. Ann Intern Med 1975;83:456-463.
4. Lesser RP, Fahn S, Snider SR, et al: Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-1260.
5. Fahn S: Fluctuations of disability in Parkinson’s disease: Pathophysiology: in Marsden CD. Fahn S (eds): Movement Disorders. London, Butter-worlhs, 1981. pp 123-145.
6. Marsden CD, Parkes JD: On-olT effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1976;i:292-296.
7. l8F)fluorodopa. an analogue of dopa. and its use in direct external measurements of slrage degradation and turnover of intracerebral dopamine. Proc Nall Sci USA 1978:75:464-467.
8. Spencer SE, Woolen GF: Altered pharmacokinetics of β-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology 1984;34:1105-1108.
9. Kurlan R, Rothficld K, Woodward WR, et al: Erratic gastric emptying of levodopa may cause’random' fluctuations of parkinsonian mobility. Neurology 1988:38:419-421.
10. Rivera-Calimlim L, Dujovne CA, Morga JP, et al: β-Dopa treatment failure: Explanation and correction. Br Med J 1970:4:93-94.
11. Leon AS, Speigel H: The effect of antiacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol 1972; 12:263-267.
12. Pocelinko R, Thomas GB, Solomon HM: The effect of an antiacid on the absorption and metabolism of levodopa. Clin Pharmacol Ther 1972:13:149.
13. Melamed E, Binon V, Zelig O: Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology 1986;36: 100-103.
14. Kurlan R, Rubin AJ, Miller C, et al: Duodenal delivery of levodopa for on-olf fluctuations in parkinsonism: Preliminary observations. Ann Neurol 1986:20:262-265.
15. Ruggieri S, Stocchi F, Carta A, et al: Jejunal delivery of levodopa methyl ester. Lancet 1989; ii:45-46.
16. Steiger M J, Stocchi F, Carta A, et al: The clinical cflieacy of oral levodopa methyl ester solution in reversing afternoon ‘otT periods in Parkinson's disease. Clin Neuropharmaeol 1991; 14:241-244.
17. Marion MH, Stocchi F, Quinn NP, Jcnner P, Marsden CD: Single dose study of slow release preparation of levodopa and benserazidc (Ma-dopar 1IBS) in Parkinson's disease. Adv Neurol 1986;45:493-496.
18. Nutt JG, Woodward WR, Carter JH, et al: Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry 1989;52:481-487.
19. Wade DN, Mearrick PT, Morris JL: Active transport of L-dopa in the intestine. Nature 1973;242:463-465.
20. Leenders KL, Poewe WH, Palmer AJ, et al: Inhibition of L-1 (”F)fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986;20:258-262.
21. Nutt JG, Woodward WR, Hammcrstad JP, et al: 'On-otT phenomenon in Parkinson’s disease: Relationship to -dopa absorption and transport. N Engl J Med 1984;310:483 -488.
22. Woodward WR, Olanow CW, Beckner BS, Hauser RA, Gauger BA, Cedarbaum JM, Nutt JG: The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: Plasma and ventricular CSF L-dopa levels and clinical responses. Neurology 1993;43:1704-1708.
23. l8F)fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213.
24. Lcenders KL, Salmon EP, Tyrrell P, et al: Nigro-striatal dopaminergic systsem assessed in-vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
25. Fabbrini G, Juncos JL, Mouradian MM, et al: Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson’s disease. Ann Neurol 1987;21:370-376.
26. Fabbrini G, Mouradian MM, Juncos JL, et al: Motor fluctuations in Parkinson's disease: Central pathophysiologic mechanisms, part I. Ann Neurol 1988;24:366-371.
27. Kashihara K, Sato Y, Fujiwara T, et al: Effects of intermittent and a continuous haloperidol administration on the dopaminergic system in the rat brain. Biol Psychiatry 1986:21:650.
28. Marsden CD, Jenner P: L-Dopa’s action in Parkinson’s disease. Trends Neurol Sei 1981;4:148-150.
29. Sage JI, Trooskin S, Sonsalla PK, et al: Longterm duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988; 24:87-89.
30. Stocchi F, Ruggieri S, Carta A, Ryatt J, Quinn N, Jenner P, Marsden CD, Agnoli A: Intravenous boluses and continuous infusion of L-dopa methyl ester in fluctuating patients with Parkinson’s disease. Mov Disord I992;3:249-256.
31. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN: Motor fluctuations in Parkinson’s disease: Central pathophysiological mechanisms, part II. Ann Neurol 1988:24: 372-378.
32. Barbeau A: L-Dopa therapy in Parkinson's disease: A critical review of nine years’ experience. Can Med Assoc J 1969; 101:791-800.
33. Colzias GC, Papavasiliou PS, Gellcne R: Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969:280:337-345.
34. Mouradian MM, Heuser IJE, Baronti F, Chase TN: Modifications of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson’s disease. Ann Neurol 1990;27:18-23.
35. Baronti F, Mouradian MM, Davis T, Giuffra M, Brughitta G, Conant K, Chase TN: Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992: 32:776-781.
36. Stocchi F, Ruggieri S, Antonini A. et al: Subcutaneous lisuride infusion in Parkinson’s disease: Clinical results using different modes of administration. J Neural Transm 1988:27(suppl):27-33.
37. Stocchi F, Ruggieri S, Viselli E, Bramante I, Monge A, Barbato L, Agnoli A: Subcutaneous lisuride infusion: in Lakke PWFJ. Delhaas EM. Rufgcrs AWF (eds): Parenteral Drug Therapy in Spasticity and Parkinson’s Disease. New Trends in Neurol. 1992, pp 205-211.
38. Montastruc JL, Rascol O, Senard JM, Rascol A: A randomised controlled study of bromocriptine secondarily associated to levodopa versus levodopa in previously untreated parkinsonian patients: A 5-year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.